Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association study

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Blake CM, Kharasch ED, Schwab M et al. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin. Pharmacol. Ther. 94(3), 394–399 (2013). •• This meta-analysis highlights the impact of CYP2D6 phenotypes on metoprolol pharmacokinetics in human subjects.
  Medline CASGoogle Scholar
• 2. Meloche M, Leclair G, Jutras M et al. Leveraging large observational studies to discover genetic determinants of drug concentrations: a proof-of-concept study. Clin. Transl. Sci. 15(4), 1063–1073 (2022). •• This cross-sectional study suggested that single, randomly collected plasma samples in biobanks could be used in genome-wide association studies to discover genetic determinants of drug pharmacokinetics.
  Medline CASGoogle Scholar
• 3. Laurent-Kenesi MA, Funck-Brentano C, Poirier JM et al. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br. J. Clin. Pharmacol. 36(6), 531–538 (1993).
  Medline CASGoogle Scholar
• 4. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1), 103–141 (2013).
  Medline CASGoogle Scholar
• 5. Caudle KE, Sangkuhl K, Whirl-Carrillo M et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin. Transl. Sci. 13(1), 116–124 (2020). • These consensus recommendations between the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group on CYP2D6 genotype-to-phenotype translations are an important step in the development of personalized medicine.
  MedlineGoogle Scholar
• 6. Berger B, Bachmann F, Duthaler U et al. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. Front. Pharmacol. 9, 774 (2018).
  MedlineGoogle Scholar
• 7. Turcot V, Brunet J, Daneault C et al. Validation of fatty acid intakes estimated by a food frequency questionnaire using erythrocyte fatty acid profiling in the Montreal Heart Institute Biobank. J. Hum. Nutr. Diet 28(6), 646–658 (2015).
  Medline CASGoogle Scholar
• 8. Chami N, Chen MH, Slater AJ et al. Exome genotyping identifies pleiotropic variants associated with red blood cell traits. Am. J. Hum. Genet. 99(1), 8–21 (2016).
  Medline CASGoogle Scholar
• 9. Monek O, Paintaud G, Bechtel Y et al. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4. Eur. J. Clin. Pharmacol. 54(1), 47–52 (1998).
  Medline CASGoogle Scholar
• 10. Lemieux Perreault LP, Provost S, Legault MA et al. pyGenClean: efficient tool for genetic data clean up before association testing. J. Bioinform. 29(13), 1704–1705 (2013).
  Google Scholar
• 11. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559–575 (2007).
  Medline CASGoogle Scholar
• 12. Price AL, Patterson NJ, Plenge RM et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38(8), 904–909 (2006).
  Medline CASGoogle Scholar
• 13. Das S, Forer L, Schönherr S et al. Next-generation genotype imputation service and methods. Nat. Genet. 48(10), 1284–1287 (2016).
  Medline CASGoogle Scholar
• 14. Loh PR, Danecek P, Palamara PF et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat. Genet. 48(11), 1443–1448 (2016).
  Medline CASGoogle Scholar
• 15. Zhou W, Nielsen JB, Fritsche LG et al. Efficiently controlling for case–control imbalance and sample relatedness in large-scale genetic association studies. Nat. Genet. 50(9), 1335–1341 (2018).
  Medline CASGoogle Scholar
• 16. Györffy BA, Tóth V, Török G et al. Synaptic mitochondrial dysfunction and septin accumulation are linked to complement-mediated synapse loss in an Alzheimer's disease animal model. Cell. Mol. Life Sci. 77(24), 5243–5258 (2020).
  Medline CASGoogle Scholar
• 17. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from next-generation sequencing data. Nucleic Acids Res. 38, e164 (2010).
  Medline CASGoogle Scholar
• 18. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308–311 (2001).
  Medline CASGoogle Scholar
• 19. Gong Y, Hu N, Ma L et al. ABTB2 regulatory variant as predictor of epirubicin-based neoadjuvant chemotherapy in luminal A breast cancer. Front. Oncol. 10, 1–11 (2020).
  MedlineGoogle Scholar
• 20. Pardiñas AF, Kappel DB, Roberts M et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry 10(3), 209–219 (2023). • This recent longitudinal cross-ancestry genome-wide association study discovered new genetic markers of clozapine metabolism, further reinforcing the importance of expanding cohorts in pharmacogenomic-pharmacokinetics investigations.
  MedlineGoogle Scholar
• 21. Fontana V, Turner RM, Francis B et al. Chromosomal region 11p14.1 is associated with pharmacokinetics and pharmacodynamics of bisoprolol. Pharmagenomics Pers. Med. 15, 249–260 (2022).
  Medline CASGoogle Scholar
• 22. Asiimwe IG, Blockman M, Cohen et al. A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan Black-African patients. Front. Pharmacol. 13, 967082–967097 (2022).
  Medline CASGoogle Scholar
• 23. Methner A, Leypoldt F, Joost P et al. Human septin 3 on chromosome 22q13.2 is upregulated by neuronal differentiation. Biochem. Biophys. Res. Commun. 283(1), 48–56 (2001).
  Medline CASGoogle Scholar
• 24. Shahin MH, Rouby NE, Conrado DJ et al. β(2)-adrenergic receptor gene affects the heart rate response of β-blockers: evidence from 3 clinical studies. J. Clin. Pharmacol. 59(11), 1462–1470 (2019). • This recent study demonstrated that the ADRB2 gene could be a predictor of heart rate response to β-blockers in hypertensive patients.
  Medline CASGoogle Scholar
• 25. Singh S, El Rouby N, McDonough CW et al. Genomic association analysis reveals variants associated with blood pressure response to beta-blockers in European Americans. Clin. Transl. Sci. 12(5), 497–504 (2019).
  Medline CASGoogle Scholar
• 26. Shahin MH, Conrado DJ, Gonzalez D et al. Genome-wide association approach identified novel genetic predictors of heart rate response to β-blockers. J. Am. Heart Assoc. 7(5), e006463 (2018).
  MedlineGoogle Scholar
• 27. Mehvar R, Brocks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J. Pharm. Pharm. Sci. 4(2), 185–200 (2001).
  Medline CASGoogle Scholar
• 28. Vashistha VK, Kumar A. Stereochemical facets of clinical β-blockers: an overview. Chirality 32(5), 722–735 (2020).
  Medline CASGoogle Scholar
• 29. Meloche M, Jutras M, St-Jean I et al. Isocyanate derivatization coupled with phospholipid removal microelution-solid phase extraction for the simultaneous quantification of (S)-metoprolol and (S)-α-hydroxymetoprolol in human plasma with LC–MS/MS. J. Pharm. Biomed. Anal. 204, 114263 (2021).
  Medline CASGoogle Scholar